{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:16:04Z","timestamp":1748909764790,"version":"3.40.5"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Antiretroviral drug combinations affect dolutegravir trough concentrations. Here, the authors focused on dolutegravir plus booster darunavir antiretroviral regimens to investigate the effect of the booster and\/or timing of drug administration on dolutegravir and darunavir plasma trough concentrations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This retrospective observational study included consecutive people with HIV (PWH) receiving dolutegravir plus booster darunavir antiretroviral regimens for at least 3 months, with at least one assessment of dolutegravir and darunavir plasma trough concentrations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 200 drug therapeutic drug monitoring results from 116 PWH were included. Dolutegravir and darunavir trough concentrations ranged, respectively, from 70 to 3648 mcg\/L and from 102 to 11,876 mcg\/L. The antiretroviral drug combination associated with the highest dolutegravir trough concentration was dolutegravir plus darunavir\/cobicistat, both once daily (1410 \u00b1 788 mcg\/L), whereas dolutegravir once daily plus darunavir\/ritonavir twice daily had the lowest trough concentrations (686 \u00b1 481 mcg\/L). Doubling the dose of dolutegravir did not significantly increase drug trough concentrations compared with that of once-daily regimens. Instead, the highest darunavir trough concentrations were with ritonavir (2850 \u00b1 1456 mcg\/L, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.05 versus cobicistat-based regimens). Doubling the drug dose resulted in a significant increase in the darunavir trough concentration (4445 \u00b1 2926 mcg\/L, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.05).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Dolutegravir trough concentrations were significantly reduced in PWH receiving darunavir\/ritonavir twice daily. This evidence should be carefully considered in clinical conditions requiring higher dolutegravir exposure, such as in the presence of drug\u2013drug interactions with drugs known to reduce dolutegravir bioavailability or in highly experienced PWH.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001259","type":"journal-article","created":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T16:17:11Z","timestamp":1725553031000},"page":"309-312","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["The Case of Dolutegravir Plus Darunavir Antiretroviral Regimens: Is It Always Useful to Double the Drug Doses?"],"prefix":"10.1097","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1512-6530","authenticated-orcid":false,"given":"Dario","family":"Cattaneo","sequence":"first","affiliation":[{"name":"Clinical Pathology Unit, ASST Fatebenefratelli Sacco;"},{"name":"Gestione Ambulatoriale Politerapie (GAP) Outpatient Clinic, ASST Fatebenefratelli Sacco;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Lisa","family":"Ridolfo","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, ASST Fatebenefratelli Sacco;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Giacomelli","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, ASST Fatebenefratelli Sacco;"},{"name":"Department of Biomedical and Clinical Sciences, University of Milan; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Castagna","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, IRCSS San Raffaele Scientific Institute, Milan, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Dolci","sequence":"additional","affiliation":[{"name":"Clinical Pathology Unit, ASST Fatebenefratelli Sacco;"},{"name":"Department of Biomedical and Clinical Sciences, University of Milan; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Spinello","family":"Antinori","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, ASST Fatebenefratelli Sacco;"},{"name":"Department of Biomedical and Clinical Sciences, University of Milan; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Gervasoni","sequence":"additional","affiliation":[{"name":"Gestione Ambulatoriale Politerapie (GAP) Outpatient Clinic, ASST Fatebenefratelli Sacco;"},{"name":"Department of Infectious Diseases, ASST Fatebenefratelli Sacco;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,9,5]]},"reference":[{"key":"R1-20250314","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.2147\/DDDT.S84850","article-title":"Dolutegravir\u2014a review of the pharmacology, efficacy, and safety in the treatment of HIV","volume":"9","author":"Kandel","year":"2015","journal-title":"Drug Des Devel Ther."},{"key":"R2-20250314","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/phar.2246","article-title":"Integrase inhibitors: after 10 years of experience, is the best yet to come?","volume":"39","author":"Brooks","year":"2019","journal-title":"Pharmacotherapy."},{"key":"R3-20250314","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/infdis\/jis750","article-title":"Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study","volume":"207","author":"Eron","year":"2013","journal-title":"J Infect Dis."},{"key":"R4-20250314","first-page":"177","article-title":"Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virus","volume":"73","author":"Castagna","year":"2018","journal-title":"J Antimicrob Chemother."},{"key":"R5-20250314","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1097\/QAD.0000000000003843","article-title":"Different effects of the companion antiretroviral drugs on dolutegravir trough concentrations: a focus on novel dual regimens","volume":"38","author":"Cattaneo","year":"2024","journal-title":"AIDS."},{"key":"R6-20250314","doi-asserted-by":"crossref","first-page":"106403","DOI":"10.1016\/j.ijantimicag.2021.106403","article-title":"Dual therapy with dolutegravir plus boosted protease inhibitor as maintenance or salvage therapy in highly experienced people living with HIV","volume":"58","author":"Lee","year":"2021","journal-title":"Int J Antimicrob Agents."},{"key":"R7-20250314","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/FTD.0000000000000273","article-title":"Comparison of the in vivo pharmacokinetics and in vitro dissolution of branded versus generic efavirenz formulation in HIV-infected patients","volume":"38","author":"Gervasoni","year":"2016","journal-title":"Ther Drug Monit."},{"key":"R8-20250314","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.jpha.2016.05.008","article-title":"Development of an HPLC-UV assay method for the simultaneous quantification of nine antiretroviral agents in the plasma of HIV-infected patients","volume":"6","author":"Charbe","year":"2016","journal-title":"J Pharm Anal."},{"key":"R9-20250314","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/FTD.0000000000000684","article-title":"Impact of therapeutic drug monitoring of antiretroviral drugs in routine clinical management of people living with HIV: a narrative review","volume":"42","author":"Cattaneo","year":"2020","journal-title":"Ther Drug Monit."},{"key":"R10-20250314","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1093\/jac\/dkx055","article-title":"Effects of ritonavir and cobicistat on dolutegravir exposure: when the booster can make the difference","volume":"72","author":"Gervasoni","year":"2017","journal-title":"J Antimicrob Chemother."},{"key":"R11-20250314","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/jac\/dkw032","article-title":"Cobicistat versus ritonavir boosting and differences in the drug\u2013drug interaction profiles with co-medications","volume":"71","author":"Marzolini","year":"2016","journal-title":"J Antimicrob Chemother."},{"key":"R12-20250314","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1124\/dmd.112.048918","article-title":"In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor","volume":"41","author":"Reese","year":"2013","journal-title":"Drug Metab Dispos."},{"key":"R13-20250314","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1002\/jcph.290","article-title":"Pharmacokinetics of darunavir in fixed-dose combination with cobicistat compared with coadministration of darunavir and ritonavir as single agents in healthy volunteers","volume":"54","author":"Kakuda","year":"2014","journal-title":"J Clin Pharmacol."},{"key":"R14-20250314","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1080\/17425255.2019.1685495","article-title":"Pharmacokinetic drug evaluation of ritonavir (versus cobicistat) as adjunctive therapy in the treatment of HIV","volume":"15","author":"Cattaneo","year":"2019","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"R15-20250314","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/QAI.0000000000000618","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate in the first protease inhibitor-based single-tablet regimen for initial HIV-1 therapy: a randomized phase 2 study","volume":"69","author":"Mills","year":"2015","journal-title":"J Acquir Immune Defic Syndr."},{"key":"R16-20250314","doi-asserted-by":"crossref","first-page":"e25072","DOI":"10.1002\/jia2.25072","article-title":"Darunavir\/cobicistat showing similar effectiveness as darunavir\/ritonavir monotherapy despite lower trough concentrations","volume":"21","author":"Gutierrez-Valencia","year":"2018","journal-title":"J Int AIDS Soc."},{"key":"R17-20250314","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/clpt.2008.302","article-title":"Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics","volume":"85","author":"Morgan","year":"2009","journal-title":"Clin Pharmacol Ther."},{"key":"R18-20250314","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s40262-020-00933-8","article-title":"Comparative population pharmacokinetics of darunavir in SARS-CoV-2 patients vs. HIV patients: the role of interleukin-6","volume":"59","author":"Cojutti","year":"2020","journal-title":"Clin Pharmacokinet."},{"key":"R19-20250314","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1093\/jac\/dkaa190","article-title":"Lopinavir\/ritonavir in COVID-19 patients: maybe yes, but at what dose?","volume":"75","author":"Baldelli","year":"2020","journal-title":"J Antimicrob Chemother."},{"key":"R20-20250314","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1111\/bcp.15538","article-title":"Inflammation and intracellular exposure of dolutegravir, darunavir, tenofovir and emtricitabine in people living with HIV","volume":"89","author":"Ferrara","year":"2023","journal-title":"Br J Clin Pharmacol"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001259","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T15:03:11Z","timestamp":1741964591000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,5]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001259","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"type":"print","value":"0163-4356"},{"type":"electronic","value":"1536-3694"}],"subject":[],"published":{"date-parts":[[2024,9,5]]},"assertion":[{"value":"2024-06-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-26","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}